Ukraine is set to produce cutting-edge medications for cancer treatment.
According to a post from the press service of the State Enterprise "Medical Procurement" on Facebook, a deal with the international pharmaceutical company Roche to localize the production of innovative oncology drugs was signed during the Ukraine Recovery Conference 2025 held in Rome.
"For the first time, our state enterprise becomes a full-fledged partner of a global leader in innovative drug development! Under the investment agreement, the Swiss company Roche will supply medications to Ukraine in bulk form, ready for packaging. Our branch «Medpostachannya» will then handle the final packaging, labeling, and distribution to patients," the announcement stated.
This will significantly reduce the cost of medications and increase the number of patients receiving modern treatment.
According to Roche's calculations, over 5 years, the investment agreement will provide medications for more than 5,800 patients," stated the State Enterprise "Medical Procurement".
Specifically, the medications will address two of the most common types of cancer in Ukraine:
- Atezolizumab (“Tecentriq”) — for the treatment of non-small cell lung cancer;
- Pertuzumab + Trastuzumab (“Phesgo”) — for treating HER2-positive breast cancer.
Ukrainian patients will be able to access these locally produced medications as early as 2027.
This collaboration will lead to significant cost reductions for medications, the development of pharmaceutical manufacturing in Ukraine, and sustained access to treatment.
On July 10-11, the fourth International Conference on Ukraine Recovery (URC2025) will take place in Rome, attended by the President of Ukraine and heads of European states.
The forum will continue a series of high-level political events aimed at rapid recovery and long-term reconstruction of Ukraine, which is suffering from external aggression. This time, the Ukrainian delegation will focus on presenting practical projects that are already being implemented even amid war or have a high degree of readiness for implementation.
